Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine crawled time : 14:30 save search
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
VBIV | $0.591 -4.68% -4.91% 370K
|
Health Technology
| Email alert
Add to watchlist
partnership vaccine platform
Vaccine research market size to grow at a CAGR of 9.88% from 2022 to 2027, Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, more to emerge as key players, Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CMXHF | $175.0 -19.21% 110
|
n/a
|
| O: 0.41%
H: 0.0%
C: 0.0%
CSLLY | $87.83 3.3% 48K
|
n/a
|
| O: -4.92%
H: 3.76%
C: 3.44%
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.4%
H: 1.49%
C: 1.49%
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
|
| O: 1.55%
H: 0.82%
C: 0.16%
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: -0.6%
H: 0.19%
C: 0.09%
ABT | News | $105.9 -3.03% 0.07% 12M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 1.08%
H: 0.82%
C: 0.67%
pharma vaccine astrazeneca research key market
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $27.68 -8.13% -8.85% 620K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Published: 2024-01-24 (Crawled : 14:30) - globenewswire.com
CAPR | $5.57 -6.07% -6.46% 480K
|
Health Technology
|
| O: 2.18%
H: 6.4%
C: -3.32%
vaccine sars-cov-2 collaboration trial therapeutics
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster S...
Published: 2023-12-01 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -0.05%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
vaccine rsv market
COVID-19 Isn’t Done with Us Yet, Vaccine Patents and a 4th Booster
Published: 2022-03-16 (Crawled : 14:30) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
covid-19 patent covid one vaccine
BioNTech to Join High-level Meeting with Partners in Marburg and to Hold Press Conference to Provide an Update on Sustainable Vaccine Manufacturing in Africa
Published: 2022-02-15 (Crawled : 14:30) - globenewswire.com
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.0%
H: 0.99%
C: 0.47%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 0.85%
H: 5.72%
C: 4.87%
conference vaccine marburg africa
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort
Published: 2022-02-15 (Crawled : 14:30) - globenewswire.com
ACIU | $2.45 0.0% 250K
|
Health Technology
|
| O: 2.07%
H: 3.61%
C: 1.58%
aci-35 alzheimer phase 1b trial phase 1 aci-35.030 vaccine alzheimer’s alzheimer's phase 2b
Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland
Published: 2022-02-14 (Crawled : 14:30) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: -3.44%
H: 2.07%
C: -7.82%
covid-19 covid authorization switzerland vaccine
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
Published: 2022-02-11 (Crawled : 14:30) - globenewswire.com
VAXX | $0.418 -4.96% -5.22% 310K
|
|
| O: 3.74%
H: 0.0%
C: 0.0%
covid-19 xin covid vaccine antibody
Thermo Fisher Scientific Earns NSF/ANSI 456 Vaccine Storage Certification for its High-Performance Refrigerators and Freezers
Published: 2022-01-25 (Crawled : 14:30) - biospace.com/
TMO | News | $547.25 -1.32% -0.02% 1.6M
|
Health Technology
|
| O: -1.25%
H: 1.47%
C: -0.15%
vaccine perform
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine
Published: 2022-01-25 (Crawled : 14:30) - biospace.com/
ANIX 4 | $3.085 -2.68% -2.76% 73K
|
Health Technology
|
| O: 0.33%
H: 3.96%
C: 1.32%
patent ovarian cancer bioscience cancer vaccine
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
IBRX | $5.25 6.71% 6.29% 4.3M
|
Manufacturing
|
| O: 1.53%
H: 1.2%
C: -2.41%
AMRS | $0.05 -21.88% -16.36% 47M
|
Process Industries
|
| O: -2.79%
H: 1.93%
C: -3.72%
als bladder cancer trials trial covid cel clinical trials cancer vaccine phase 3 merge t-cell bladder
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 11.76%
H: 2.83%
C: -12.2%
covid-19 europe covid authorization positive vaccine
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
CAPR | $5.57 -6.07% -6.46% 480K
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
covid-19 therapeutics covid vaccine
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
MRNA | News S | $103.45 -0.33% -0.33% 2M
|
Health Technology
|
| O: -17.85%
H: 0.0%
C: 0.0%
covid-19 covid vaccine
NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine Trials
Published: 2021-12-09 (Crawled : 14:30) - globenewswire.com
NRXP | News 0 d | $4.17 -3.02% -3.12% 91K
|
Manufacturing
|
| O: 0.67%
H: 5.85%
C: -3.34%
covid-19 zyesami health trials trial covid vaccine brilife
Janssen Announces Respiratory Syncytial Virus (RSV) Adult Vaccine Candidate Maintains High Efficacy Regardless of Lower Respiratory Tract Disease Severity
Published: 2021-12-07 (Crawled : 14:30) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
respiratory disease vaccine
NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other Regions
Published: 2021-12-06 (Crawled : 14:30) - globenewswire.com
NRXP | News 0 d | $4.17 -3.02% -3.12% 91K
|
Manufacturing
|
| O: -1.09%
H: 0.0%
C: 0.0%
israel phase 2 europe phase 2b trial vaccine brilife
GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress
Published: 2021-12-03 (Crawled : 14:30) - globenewswire.com
GOVX | $1.49 -2.61% -2.68% 29K
|
Health Technology
|
| O: -2.3%
H: 2.06%
C: -3.66%
immunotherapy therapy vaccine
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.